SUPN Relative Valuation
SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SUPN is overvalued; if below, it's undervalued.
Historical Valuation
Supernus Pharmaceuticals Inc (SUPN) is now in the Fair zone, suggesting that its current forward PE ratio of 17.54 is considered Fairly compared with the five-year average of 21.48. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 41.41 to 65.60 according to relative valuation methord.
Relative Value
Fair Zone
41.41-65.60
Current Price：45.10
Fair
17.54
PE
1Y
3Y
5Y
Trailing
Forward
12.22
EV/EBITDA
Supernus Pharmaceuticals Inc. (SUPN) has a current EV/EBITDA of 12.22. The 5-year average EV/EBITDA is 13.54. The thresholds are as follows: Strongly Undervalued below 1.86, Undervalued between 1.86 and 7.70, Fairly Valued between 19.38 and 7.70, Overvalued between 19.38 and 25.22, and Strongly Overvalued above 25.22. The current Forward EV/EBITDA of 12.22 falls within the Historic Trend Line -Fairly Valued range.
14.09
EV/EBIT
Supernus Pharmaceuticals Inc. (SUPN) has a current EV/EBIT of 14.09. The 5-year average EV/EBIT is 4.54. The thresholds are as follows: Strongly Undervalued below -222.15, Undervalued between -222.15 and -108.80, Fairly Valued between 117.88 and -108.80, Overvalued between 117.88 and 231.23, and Strongly Overvalued above 231.23. The current Forward EV/EBIT of 14.09 falls within the Historic Trend Line -Fairly Valued range.
3.13
PS
Supernus Pharmaceuticals Inc. (SUPN) has a current PS of 3.13. The 5-year average PS is 2.79. The thresholds are as follows: Strongly Undervalued below 2.02, Undervalued between 2.02 and 2.41, Fairly Valued between 3.18 and 2.41, Overvalued between 3.18 and 3.57, and Strongly Overvalued above 3.57. The current Forward PS of 3.13 falls within the Historic Trend Line -Fairly Valued range.
12.97
P/OCF
Supernus Pharmaceuticals Inc. (SUPN) has a current P/OCF of 12.97. The 5-year average P/OCF is 9.70. The thresholds are as follows: Strongly Undervalued below 3.69, Undervalued between 3.69 and 6.69, Fairly Valued between 12.70 and 6.69, Overvalued between 12.70 and 15.70, and Strongly Overvalued above 15.70. The current Forward P/OCF of 12.97 falls within the Overvalued range.
22.40
P/FCF
Supernus Pharmaceuticals Inc. (SUPN) has a current P/FCF of 22.40. The 5-year average P/FCF is 20.13. The thresholds are as follows: Strongly Undervalued below 9.67, Undervalued between 9.67 and 14.90, Fairly Valued between 25.36 and 14.90, Overvalued between 25.36 and 30.59, and Strongly Overvalued above 30.59. The current Forward P/FCF of 22.40 falls within the Historic Trend Line -Fairly Valued range.
Supernus Pharmaceuticals Inc (SUPN) has a current Price-to-Book (P/B) ratio of 2.45. Compared to its 3-year average P/B ratio of 1.95 , the current P/B ratio is approximately 25.63% higher. Relative to its 5-year average P/B ratio of 1.97, the current P/B ratio is about 24.78% higher. Supernus Pharmaceuticals Inc (SUPN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.10%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.45% , the current FCF yield is about -100.00% lower.
2.45
P/B
Median3y
1.95
Median5y
1.97
2.76
FCF Yield
Median3y
7.10
Median5y
7.45
Competitors Valuation Multiple
The average P/S ratio for SUPN's competitors is , providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 9.34%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SUPN increased by 24.72% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -40.93 to -132.04.
The secondary factor is the Revenue Growth, contributed 9.34%to the performance.
Overall, the performance of SUPN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Supernus Pharmaceuticals Inc (SUPN) currently overvalued or undervalued?
What is Supernus Pharmaceuticals Inc (SUPN) fair value?
How does SUPN's valuation metrics compare to the industry average?
What is the current P/B ratio for Supernus Pharmaceuticals Inc (SUPN) as of Dec 05 2025?
What is the current FCF Yield for Supernus Pharmaceuticals Inc (SUPN) as of Dec 05 2025?
What is the current Forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN) as of Dec 05 2025?